Lamivir-S Baby/Junior is intended for use in children weighing 30 Kgs who are just initiating therapy with Triomune Baby/Junior.

Each Uncoated Dispersible Tablet Baby ContainsLamivudine 30mgStavudine 6mg :
b
Satvudine 6mg
Lamivudine 30mg
/b
Each Uncoated Dispersible Tablet Junior Contains Lamivudine 60mgStavudine 12mg :b
Satvudine 12mg
Lamivudine 60mg
/b


bPlease email for Dosage Chart.

Consult your health care professional before taking this combination and take exactly as prescribed. /b

Lactic Acidosis and severe Hepatomegaly with steatosis including fatal cases have been reported with the use of neucleoside analogues alone or in combination including lamivudine and stavudine.

This medication is contra indicated in patients with clinically significant hypersensitivity to any of the components contained in the formulation.

b Lamivudine : /b There is no known antidote for Lamivudine. It is not known whether lamivudine can be removed by peritoneal dyalisis or haemodialysis.

b Stavudine : /b Stavudine can be removed by haemodialysis. Experience with adults treated with 12 to 24 times the recommended daily dosage revealed no acute toxicity. Complications of chronic overosage include peripheral neuropathy and hepatic toxicity.

When stavudine is used in combination with other agents with similar toxicities the incidence of adverse events may be higher than when stavudine is used alone. Pancreatitis Peripheral neuropathy and liver function abnormalities occur more frequently in patients treated with the combination of stavudine.

b The duration of clinical benefit from antiretroviral therapy may be limited. Patients recieving nevirapine or any other antiretroviral therapy may continue to devleop opportunistic infections and other complications of HIV infection and therefore should remain under close clinical observation by physicians experienced in the treatment of patients with associated HIV diseases. /b

Do not double dose to make up for the missed dose. Consult your doctor for dosages and take exactly as directed.

This formulation is intended to facilitate the 14 day Lead in Dosing of Nevirapine.

Store in a cool dry place.

Stavudine therapy has rarely been associated with motor weakness occuring predominantly in the setting of lactic acidosis. The evolution of motor weakness may mimic the clinical presentation of the Guillian-Barre Syndromeincluding respiratory failure. Symptoms may continue or worsen following discontinuation of therapy.

Stavudine therapy has also been associated with peripheral sensory neuropathy which can be severe is dose related and occurs more frequently in patients being treated with neurotoxic drug therapy including didanosine in patients with advanced HIV infection or in patients who have previously experienced peripheral neuropathy.

Caregivers of young children recieving stavudine therapy should be instructed regarding detection and reporting of peripheral neuropathy.